- Home
- Products
TAFINLAR (Dabrafenib)
TAFINLAR (Dabrafenib)
- Medicine Name: TAFINLAR
- Generic Name: Dabrafenib
- Dosage Form & Strength: 50 mg and 75 mg Capsules
- Manufactured By: Novartis
TAFINLAR (Dabrafenib) is an FDA-approved BRAF kinase inhibitor used for the treatment of patients with:
- Unresectable or metastatic melanoma with BRAF V600E mutation (as a single agent)
- Unresectable or metastatic melanoma with BRAF V600E or V600K mutations (in combination with Trametinib)
The combination therapy has demonstrated improved response rates and is recommended when confirmed by an FDA-approved diagnostic test.
Tafinlar may cause new primary malignancies, including cutaneous squamous cell carcinoma. Regular dermatologic evaluation is advised.
Serious febrile reactions have occurred. Monitor for signs of fever and interrupt treatment if needed.
Hyperglycemia has been reported in patients with and without pre-existing diabetes. Blood glucose levels should be monitored regularly.
Hemorrhagic events, uveitis, and QT prolongation may occur. Patients should be monitored and managed accordingly.
Embryo-fetal toxicity: Dabrafenib may cause fetal harm. Women of reproductive age should use effective contraception during and for 2 weeks after treatment.
Avoid use in combination with strong CYP3A4 or CYP2C8 inducers or inhibitors unless absolutely necessary.
Breastfeeding is not recommended during treatment and for a minimum of 2 weeks after the last dose.
To access TAFINLAR (Dabrafenib) through GlobalRareMeds, patients must submit the following documents:
- Valid prescription from a qualified oncologist
- Diagnostic reports confirming BRAF V600 mutation status
- Government-issued patient ID
Order Confirmation:
Orders will only be processed after submission and verification of the above documents and, if required, an import permit.
Tafinlar is a prescription-only medication, available through named-patient supply provisions in India and globally.
GlobalRareMeds sources Tafinlar 50 mg and 75 mg capsules from certified international suppliers across the USA, Canada, Europe, and Australia.
Our fulfillment center in Ambernath, Thane District ensures secure storage, pharmacist-reviewed order processing, and prompt dispatch to:
- India’s major cities – Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Ahmedabad, Pune, and others
- International markets, depending on legal import requirements
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name of Tafinlar?
A. The generic name is Dabrafenib.
Q. Who manufactures Tafinlar?
A. Tafinlar is manufactured by Novartis.
Q. Is Tafinlar FDA approved?
A. Yes, Tafinlar received FDA approval in 2013.
Q. What strengths is Tafinlar available in?
A. Tafinlar is available in 50 mg and 75 mg capsules for oral use.
Q. What does Tafinlar treat?
A. Tafinlar is indicated for BRAF V600E mutation-positive metastatic melanoma as monotherapy and for BRAF V600E or V600K mutation-positive melanoma in combination with Trametinib.
Q. Can Tafinlar be taken during pregnancy or breastfeeding?
A. No. Tafinlar may cause fetal harm. Women must avoid pregnancy during treatment and for 2 weeks afterward. Breastfeeding is also not recommended during this period.
Q. How should Tafinlar be stored?
A. Store at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). Keep in original container.
Q. How can I purchase Tafinlar in India?
A. Submit a valid prescription and diagnostic report to GlobalRareMeds. We will guide you through the process and arrange delivery after verifying legal compliance.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
